The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution

The visualisation and quantitative analysis of the native drug distribution in a pre-clinical or clinical setting are desirable for evaluating drug effects and optimising drug design. Here, using matrix-assisted laser desorption ionisation imaging mass spectrometry (MALDI-IMS) with enhanced resolution and sensitivity, we compared the distribution of a paclitaxel (PTX)-incorporating micelle (NK105) with that of PTX alone after injection into tumour-bearing mice. We demonstrated optically and quantitatively that NK105 delivered more PTX to the tumour, including the centre of the tumour, while delivering less PTX to normal neural tissue, compared with injection with PTX alone. NK105 treatment yielded a greater antitumour effect and less neural toxicity in mice than did PTX treatment. The use of high-resolution MALDI-IMS may be an innovative approach for pharmacological evaluation and drug design support.

[1]  Y. Matsumura Cancer stromal targeting (CAST) therapy. , 2012, Advanced drug delivery reviews.

[2]  D. Cunningham,et al.  Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours , 2013, The British journal of surgery.

[3]  K. Kataoka,et al.  Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.

[4]  D. Ettinger,et al.  Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Kristina Schwamborn,et al.  Molecular imaging by mass spectrometry — looking beyond classical histology , 2010, Nature Reviews Cancer.

[6]  Bernhard Spengler,et al.  Mass spectrometry imaging with high resolution in mass and space , 2013, Histochemistry and Cell Biology.

[7]  Alnawaz Rehemtulla,et al.  PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. , 2008, Current computer-aided drug design.

[8]  K. Kataoka,et al.  NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.

[9]  E K Rowinsky,et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Cain,et al.  The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Syrigos,et al.  Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer , 2012, Therapeutic advances in medical oncology.

[12]  Takahiro Hayasaka,et al.  Development of imaging mass spectrometry. , 2012, Biological & pharmaceutical bulletin.

[13]  M. R. Groseclose,et al.  MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. , 2011, Bioanalysis.

[14]  W. Pao,et al.  Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. , 2013, AJR. American journal of roentgenology.

[15]  Michelle L. Reyzer,et al.  MALDI imaging mass spectrometry: molecular snapshots of biochemical systems , 2007, Nature Methods.

[16]  M. Suematsu,et al.  Visualization of volatile substances in different organelles with an atmospheric-pressure mass microscope. , 2009, Analytical chemistry.

[17]  L. Pusztai,et al.  Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer , 2013, Clinical Cancer Research.

[18]  H. Ueno,et al.  A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation , 2007, British Journal of Cancer.

[19]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[20]  O. Ovchinnikova,et al.  Laser microdissection and atmospheric pressure chemical ionization mass spectrometry coupled for multimodal imaging. , 2013, Rapid communications in mass spectrometry : RCM.

[21]  Brian Samuels,et al.  Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[23]  P. Workman,et al.  Discovering novel chemotherapeutic drugs for the third millennium. , 1999, European journal of cancer.

[24]  Joe W. Gray,et al.  Translating insights from the cancer genome into clinical practice , 2008, Nature.

[25]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[26]  T. Yoshikawa,et al.  Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer , 2012, Investigational New Drugs.